Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
188 Clinical Paid Trials near Cincinnati, OH
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDaridorexant for PTSD
Fort Thomas, Kentucky
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Narcolepsy, Others
Must Not Be Taking:Daridorexant
200 Participants Needed
VLS-1488 for Advanced Cancer
Cincinatti, Ohio
This trial tests VLS-1488, a new drug for advanced cancers, to find the safest and most effective dose. It targets patients needing new treatment options and checks how the drug interacts with other medications and food.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Issues, Others
Must Not Be Taking:CYP3A Inhibitors, MDR1 Inhibitors
200 Participants Needed
XTMAB-16 for Sarcoidosis
Cincinnati, Ohio
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, CNS Sarcoidosis, Congestive Heart Failure, Others
Must Be Taking:Prednisone, Methotrexate, Azathioprine, Others
94 Participants Needed
TAC01-CLDN18.2 Engineered T-cells for Cancer
Cincinnati, Ohio
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor.
This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Pathology, Active Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
113 Participants Needed
TN-201 for Hypertrophic Cardiomyopathy
Cincinnati, Ohio
This trial tests a new drug, TN-201, in adults with a specific genetic heart condition. It aims to see if the drug is safe and how it affects their health over several years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:High AAV9 Antibody Titer
30 Participants Needed
IMPT-314 for Non-Hodgkin's Lymphoma
Cincinnati, Ohio
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active CNS Involvement, Cardiac Lymphoma, Others
Must Not Be Taking:Immune Checkpoint Inhibitors
270 Participants Needed
Gene Therapy for Hearing Loss
Cincinnati, Ohio
This trial tests a new gene therapy delivered to the ear to help people with hearing issues. The therapy aims to improve ear cell function by introducing a healthy gene. Two different doses will be tested to ensure safety and effectiveness. Gene therapy has emerged as a promising strategy for treating hearing loss by addressing genetic dysfunction.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Ear Infections, Cochlear Implants, Others
18 Participants Needed
Gene Therapy for Congenital Hearing Loss
Cincinnati, Ohio
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene.
The purpose of this study is to:
* Learn about the safety of DB-OTO
* Determine how well DB-OTO is tolerated (does not cause ongoing discomfort)
* Evaluate the efficacy of DB-OTO (how well DB-OTO works)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:< 17
Key Eligibility Criteria
Disqualifiers:Cochlear Implants, Malignancies, Meningitis, Others
30 Participants Needed
PMT Therapy for Pulmonary Alveolar Proteinosis
Cincinnati, Ohio
The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Other PAP Diseases, Pulmonary Fibrosis, Chronic Infections, Alcohol Abuse, Drug Abuse, Others
3 Participants Needed
Intranasal COVID Vaccine for COVID-19
Cincinnati, Ohio
This trial tests a nasal spray vaccine called CVXGA for COVID-19 in healthy adults aged 18-80. The vaccine uses a harmless virus to help the body learn to fight COVID-19. Participants will be monitored for several months after receiving one dose.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Covid History, Immunocompromised, Others
Must Not Be Taking:Intranasal Medications
227 Participants Needed
RSV Vaccine for Respiratory Syncytial Virus
Cincinnati, Ohio
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 5
Key Eligibility Criteria
Disqualifiers:Chronic Disease, Pulmonary Abnormality, Neurological Conditions, Others
Must Not Be Taking:Immunosuppressants, Systemic Steroids, Intranasal Meds, Others
137 Participants Needed
Afamitresgene Autoleucel for Pediatric Cancer
Cincinnati, Ohio
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:2 - 21
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, CNS Metastases, Others
Must Not Be Taking:Fludarabine, Cyclophosphamide
20 Participants Needed
CIML-NK Cells for Acute Myeloid Leukemia
Cincinnati, Ohio
This trial tests a new treatment using enhanced donor immune cells for patients with tough-to-treat leukemia. These special cells are designed to better remember and attack cancer cells. The goal is to see if this approach is safe and effective for these patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:2+
Key Eligibility Criteria
Disqualifiers:CNS Disease, APML, Uncontrolled Infection, Others
Must Not Be Taking:Prednisone, Investigational Therapies
20 Participants Needed
NC410 + Pembrolizumab for Advanced Cancer
Edgewood, Kentucky
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Infection, HIV, Hepatitis, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
97 Participants Needed
AM3101 for Meniscus Tears
Cincinnati, Ohio
This trial tests AM3101, a treatment for knee injuries, on patients with meniscal tears needing repair. It aims to help the knee tissue heal better after surgery, reducing complications.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Arthritis, Pregnancy, Drug Dependence, Others
Must Not Be Taking:Statins
74 Participants Needed
Ipatasertib + Megestrol Acetate for Endometrial Cancer
Cincinnati, Ohio
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypercholesterolemia, Liver Disease, Others
Must Not Be Taking:AKT Inhibitors, Strong CYP3A Inhibitors
96 Participants Needed
Selinexor + Temozolomide for Recurrent Glioblastoma
Cincinnati, Ohio
This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Pregnant, Severe COVID-19, Others
Must Not Be Taking:Bevacizumab, Dacarbazine
97 Participants Needed
Ribociclib + Topotecan + Temozolomide for Neuroblastoma
Cincinnati, Ohio
This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Heart Disease, QTc Prolongation, Others
Must Not Be Taking:CYP3A4/5 Drugs
231 Participants Needed
New Treatments for PTSD
Fort Thomas, Kentucky
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts; treatment-specific procedures will be described in the Master Protocol cohort-specific appendices. Individual cohorts may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in corresponding intervention-specific clinicaltrials.gov records.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Suicide Risk, Substance Use, Others
Must Not Be Taking:Psychiatric Medications
800 Participants Needed
Tiragolumab + Atezolizumab for Solid Tumors
Cincinnati, Ohio
This trial studies how well tiragolumab and atezolizumab work in children and adults with difficult-to-treat tumors missing specific genes. These treatments help the immune system attack cancer and stop it from growing. Atezolizumab is an antibody that has been used with other treatments for various cancers.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Autoimmune, Hepatitis, Others
Must Not Be Taking:Systemic Steroids, Immunosuppressants
86 Participants Needed
Why Other Patients Applied
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
Lutathera for Brain Tumor
Cincinnati, Ohio
This trial tests Lutathera, a radioactive drug given through an IV, in patients with certain brain tumors that haven't responded to other treatments. The drug attaches to cancer cells and uses radiation to kill them.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:4 - 39
Key Eligibility Criteria
Disqualifiers:Bone Marrow Metastasis, Bulky Disease, Breast-feeding, Type I Diabetes, Others
Must Not Be Taking:Anti-cancer Drugs
65 Participants Needed
Gene Therapy for Hereditary Angioedema
Cincinnati, Ohio
This trial tests BMN 331, a gene therapy given through an IV, for people with hereditary angioedema (HAE) who lack a specific protein. The therapy uses a virus to deliver a healthy gene to liver cells, enabling them to produce the missing protein. The study aims to see if this treatment is safe and effective over several years. BMN 331 is a gene therapy that uses a virus to deliver a healthy gene to liver cells, a method that has shown promise in treating various genetic disorders.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Infection, Malignancy, Liver Disease, Others
Must Be Taking:HAE Medications
44 Participants Needed
Selinexor + Radiation for Brain Cancer
Cincinnati, Ohio
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Organ Transplant, Others
Must Not Be Taking:Investigational Drugs, Anti-cancer Agents
132 Participants Needed
Elimusertib for Solid Cancers
Cincinnati, Ohio
This trial tests elimusertib, a pill that blocks enzymes needed for cancer cell growth, in children and young adults with difficult-to-treat cancers. The drug aims to stop cancer cells from repairing and growing.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12 - 30
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active CNS Metastasis, Infection, Others
Must Not Be Taking:CYP3A4 Drugs
31 Participants Needed
Losartan for Sickle Cell Disease
Cincinnati, Ohio
This trial is testing losartan, a blood pressure medication, in patients aged 6 and older with Sickle Cell Disease. The goal is to see if it can safely reduce fluid buildup in the body over time.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:6+
Key Eligibility Criteria
Disqualifiers:Chronic Transfusion, Congenital Heart Disease, Others
Must Be Taking:Sickle Cell Therapies
24 Participants Needed
STMC-103H for Allergies
Cincinnati, Ohio
This trial is testing a new treatment called STMC-103H to see if it can help prevent allergic diseases in young children. The study focuses on babies and infants who are at risk of developing allergies. The treatment aims to improve their immune system's response to allergens, potentially reducing conditions like atopic dermatitis.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:0 - 14
Key Eligibility Criteria
Disqualifiers:Congenital Abnormalities, Immune Deficiency, Others
Must Not Be Taking:Systemic Antibiotics
264 Participants Needed
Asciminib for Pediatric Chronic Myeloid Leukemia
Cincinnati, Ohio
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1 - 17
Key Eligibility Criteria
Disqualifiers:T315I Mutation, Cardiac Abnormality, Pancreatitis, Others
Must Be Taking:TKIs
44 Participants Needed
CBL0137 for Cancer
Cincinnati, Ohio
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Peripheral Vascular Disease, Others
Must Not Be Taking:Corticosteroids, Anti-cancer Agents, CYP3A4 Drugs, Others
63 Participants Needed
129Xe MRI for Interstitial Lung Disease
Cincinnati, Ohio
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cardiac Arrhythmia, Cardiac Arrest, Others
147 Participants Needed
Tegavivint for Recurrent or Refractory Cancer
Cincinnati, Ohio
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 30
Key Eligibility Criteria
Disqualifiers:Pregnancy, Brain Tumors, CNS Metastasis, Others
Must Not Be Taking:CYP3A4 Inducers/inhibitors, Bisphosphonates
147 Participants Needed
Know someone looking for new options?
Spread the word